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Abstract 
Abnormal sleep may associate with cognitive decline in Parkinson’s disease (PD).  Furthermore, sleep 
dysfunction may associate with worse motor outcome.  We hypothesised that PD patients with poor 
quality sleep would have greater progression in gait dysfunction, due to structural and functional 
overlap in networks subserving sleep and gait regulation. 12 PD patients and 12 age-matched 
controls completed longitudinal follow-up over 36 months. Poor sleep efficiency and greater sleep 
fragmentation correlated significantly with progression of step-width variability, a gait characteristic 
mediated by postural control, providing evidence that poor sleep in PD is associated with a more 
rapid deterioration in gait.  
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Sleep dysfunction is an integral component of Parkinson’s disease (PD), affecting 42-98% of 
patients.[1, 2]  Rapid Eye Movement sleep behaviour disorder (RBD) is the prototypical sleep 
disorder associated with PD, but fragmented sleep in PD is multifactorial with a multitude of primary 
and secondary sleep disorders represented. Converging evidence from animal models of sleep 
deprivation and prospective human studies implicate poor sleep as a harbinger of cognitive 
decline.[3]  Furthermore, changes in sleep architecture in early PD may predict progression to PD 
dementia.[4] The pathophysiological processes underpinning sleep dysfunction in PD are debated, 
but probably relate to a predilection of α-synuclein pathology for certain brainstem structures. The 
pedunculopontine nucleus (PPN), in particular, is pivotal in the regulation of the normal sleep-wake 
cycle; PPN cholinergic neurons display selective vulnerability in PD.[5] The PPN is also implicated in 
postural control and has attracted interest recently as a deep brain stimulation target for non-dopa-
responsive axial symptoms in PD. Although numbers studied are small, it is notable that significant 
improvements in both daytime somnolence and nocturnal sleep stability have been described.[6] 
Additionally, data from large, prospective population studies demonstrate a link between 
objectively-recorded poor quality sleep and poor motor outcomes.[7] In normal older individuals, 
decreased gait velocity and increased gait variability, particularly in the context of dual-task walking 
conditions, are associated with poor sleep quality.[8]  RBD, often a syndromic prelude to PD, is 
associated with subtle gait changes, particularly gait variability.[9] Secondary analysis of gait 
differences between our early PD cohort and age-matched controls [10] showed that step width 
variability was the most discriminatory gait measure in early PD (more so than gait speed and the 
variability of step length or time)[11].  
 
We hypothesised that early sleep dysfunction in PD would predict more rapid deterioration in gait 
and sought to explore this in a well-characterised, incident PD cohort. 
Participants were recruited from the Incidence of Cognitive Impairment in Cohorts with Longitudinal 
Evaluation- PD (ICICLE-PD) study; recruitment protocols and detailed methodology have been 
described previously.[12]  The collaborative ICICLE-GAIT study recruited contemporaneously from 
within the same cohort. Briefly, newly diagnosed patients with idiopathic PD were recruited; those 
with significant memory impairment (Mini-Mental State Examination (MMSE) score <24), or meeting 
Movement Disorders Society (MDS) criteria for dementia, were excluded. Healthy, age-matched 
controls were recruited through community sources. The studies were approved by the local 
Research Ethics Committee; participants provided written informed consent. Participants who 
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completed all elements of the study underwent ICICLE-PD assessments at baseline and 36-month 
follow-up visits. 
This comprised medical assessment by a physician, recording demographics, educational exposure 
and medication use (including hypnotics). Motor phenotype was classified, and disease severity was 
rated by Hoehn & Yahr stage. Motor disability was assessed by the MDS Revised Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS). Levodopa-equivalent dose (LED) was also calculated.  MMSE and 
Montreal Cognitive Assessment (MoCA) were used to assess global cognitive function. [13] Cognitive 
sub-domains were assessed by previously described methods. [14] Depression was rated with the 
Geriatric Depression Scale-15 (GDS-15).  
Sleep was assessed at baseline, as described previously.[15] Patients participated in a semi-
structured clinical interview with a specialist sleep physician, in addition to completing self-rated 
questionnaires (the Epworth Sleepiness Score and the Pittsburgh Sleep Quality Index). Patients and, 
where possible, bed partners completed an attenuated version of the Mayo Sleep Questionnaire, 
validated for probable RBD. Patients underwent one night of sleep respiratory home monitoring 
(Embletta) and three nights of lower limb actigraphy (CamNtech, Cambridge, UK) to measure 
periodic limb movements of sleep (PLMS). A cohort of participants then completed two weeks of 
wrist actigraphy using the same monitors, keeping contemporaneous sleep diaries.  
Gait was assessed at baseline and 36 months, using single-task and dual-task paradigms, as 
described previously.[10] Briefly, assessments were performed using a 7-m-long x 0.6-m-wide 
instrumented walkway (GAITRite, CIR Systems, USA). Participants walked at their preferred pace for 
two minutes around a 25-m circuit incorporating the walkway. PD participants were tested 
approximately one hour after medication intake. For dual-task assessment, each participant 
completed the same circuit whilst repeating string of numbers, the length of which was set at their 
seated maximum forward digit span. Gait characteristics were selected in keeping with a previously 
published  model of gait validated in PD.[16] Variability characteristics were calculated using the 
within-person standard deviation (SD); asymmetry was calculated as the absolute difference 
between the mean of left and right steps. 
Actigraphic data was computed by customised software (CamNtech, UK). For lower limbs, this 
produced a periodic limb movement index (PLMI); for wrist actigraphy this generated an estimate of 
total sleep time, sleep efficiency (SE) and a sleep fragmentation index (SFI). Pearson and Spearman 
correlations (and subsequent partial correlations) were performed using SPSS (v.22, IBM). 
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Twelve PD patients and twelve control participants completed baseline and 36 month assessments. 
Relevant clinical and demographic data are presented in Table 1. One PD participant took a hypnotic 
agent PRN during the two week period of wrist actigraphy. One PD participant had moderately 
severe obstructive sleep apnoea with an apnoea-hypopnoea index of 15.0/hr; five PD participants 
had PLMI >5.0/hr, of which four were >15.0/hr – two of these patients satisfied diagnostic criteria 
for Restless Legs Syndrome (RLS) in wakefulness. Three patients had probable RBD. 
There were no significant correlations at baseline between sleep parameters and gait characteristics. 
However, unfavourable baseline sleep indices correlated with greater change at 36 month follow-up 
in gait parameters associated with postural control (Table 1; Figure 1). Poorer SE was associated with 
greater increase in step width in controls (Pearson’s r = 0.630; p<0.05), and greater step width 
variability in PD (Pearson’s r = 0.723; p<0.01). These associations were also evident under dual task 
conditions. Higher levels of sleep fragmentation were associated with an increased single-task step 
width over the 36 months in PD only (Pearson’s r = 0.588; p<0.05) as well as increased dual-task step 
width variability in PD (Pearson’s r = 0.844; p=0.001). Cohen’s d effect size was 0.95 for the group 
difference in change of step width variability over 36 months, for both single- and dual-task step 
width variability. 
Partial correlations confirmed that increased step width variability in PD participants with impaired 
sleep (poorer SE, r2 = 0.576 and higher SFI, r2 = 0.712) was independent of global cognition, as 
assessed by MOCA; it was also independent of measures of attention. There was no relationship 
between either baseline sleep efficiency or sleep fragmentation index with evolution in LED or motor 
UPDRS scores (36 month mean +/- SD, 598.4 +/- 275.5; 40.6 +/- 10.0, respectively). There was no 
correlation between subjective sleep quality scores (ESS, PSQI) and gait characteristics; data derived 
from patient diaries did not reveal a relationship between extent of daytime napping and 
progression in gait disturbance. 
Sleep quality, previously a “Cinderella” topic in neurodegenerative research, is attracting increasing 
attention as a window to the underlying pathophysiological cascade. The mechanisms regulating 
sleep quality are complex, with numerous brain regions implicated. However, the close anatomical 
and functional proximity between sleep and gait control centres makes the hypothesis that 
dysfunction in one domain will lead to abnormalities in the other an attractive one. 
Our study highlights an association in an incident PD cohort between poor sleep and more rapid 
deterioration of gait-related postural control. We found a relationship between both poor sleep 
efficiency and higher indices of sleep fragmentation and greater step width variability in PD 
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participants. People with early PD can present with a less variable step width, possibly reflecting an 
inability to adapt to dynamic locomotor challenges.[10] However, excessive step width variability 
may manifest with disease progression and has been associated with balance impairment[17] and 
higher risk of falls[18] in elderly community-dwelling individuals, and a trend toward greater fall risk 
in PD [19]. Whilst aberrant sleep patterns may be associated with broadscale effects over time, in 
that some adverse associations were also seen in our control group, it is conceivable that the 
deleterious impact of poor quality sleep is magnified in the setting of a disease affecting gait, 
particularly aspects mediated by postural control, hence the more compelling results in the PD 
group. It may be that patients with PD exhibit greater vulnerability to the ageing process. 
Furthermore, the association continues to hold after controlling for cognition, raising the tantalising 
prospect that the observation in this small, exploratory study may unveil a hitherto under-
recognised link between sleep and gait in PD. Recent data from another group interrogating the 
functional neuroanatomy of pedunculopontine nucleus networks [20] have also suggested a link 
between disturbed sleep and postural control impairments in PD. 
We acknowledge the small participant number involved as a limitation of this study. This reflects the 
proportion of subjects from the larger ICICLE and ICICLE-GAIT studies who completed all components 
of each assessment over time, and as such represents a small, but deeply phenotyped nested cohort.  
The small sample size precludes use of more definitive statistical analysis; nonetheless the 
association between sleep and gait characteristics related to postural control was robust. 
Furthermore, the consistency of the association across single- and dual-task protocols makes the 
possibility of Type I error less likely. Employing wrist actigraphy rather than full polysomnography 
may be considered a limitation, but wrist actigraphy is an established  marker of sleep fragmentation 
in PD; furthermore in our study, sleep-disordered breathing and PLMS were sought and quantified.  
Sleep disturbance in PD has multiple causes including sleep-disordered breathing, RBD, RLS and 
asymptomatic PLMS. To our knowledge, this is the first study to address a relationship between 
sleep indices and gait outcomes in an incident PD cohort. The suggestion that poor sleep, which is 
frequently remediable, may be associated with unfavourable motor progression warrants greater 
exploration in larger prospective studies.  
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Table 1 Participant characteristics and gait performance as baseline and change in gait  
 Variable Baseline   Change over 36 months 
   Controls (n=12) PD (n=12)  Controls (n=12) PD (n=11) 
 Number of Participants 12 12 
 
- - 
 Gender ratio (M:F) 8:4 9:3 
 
- - 
 Age (years) 69.0 (6.0) 64.6 (11.3) 
 
- - 
 Duration of education (years) 12.9 (3.3) 13.2 (4.2) 
 
- - 
 MoCA 27.4 (2.5) 25.2 (2.6)* 
 
- - 
 GDS 0.8 (0.9) 3.0 (3.1)* 
 
- - 
 Disease duration (months) - 6.1 (3.5) 
 
- - 
 MDS-UPDRS part III - 23.4 (9.3) 
 
- - 
 Hoehn and Yahr Stage (n) - Stage 1: 6 
 
- - 
 
  
Stage 2: 6 
 
- - 
Levodopa-equivalent dose (LED) - 130.4 (120.0) 
 
- - 
 Motor Phenotype - PIGD: 3 
 
- - 
 
  
Tremor-dominant: 8 
 
- - 
  
Indeterminate: 1 
 
- - 
Epworth Sleepiness Score 3.8 (3.0) 7.7 (4.7)* 
 
- - 
 Pittsburgh Sleep Quality Index 4.8  (3.0) 5.8 (4.4) 
 
- - 
 Total sleep time (hrs)                                  6.9  (0.4) 7.0 (0.9) - - 
 Sleep efficiency (%) 86.7 (5.3) 87.2 (5.7) 
 
- - 
 Sleep fragmentation index 36.9 (16.7) 38.6 (16.3) 
 
- - 
 
      Single-task  
     Pace Step velocity (m/s) 1.26 (.13) 1.10 (.25) 
 
-.0007 (.1342) -.0512 (.1195) 
 Step Length (m) .70 (.06) .61 (.1)* 
 
-.0136 (.0526) -.0293 (.0464) 
 Swing time sd (ms) 14.65 (5.62) 16.6 (5.83) 
 
-4.048 (15.7036) -1.82 (19.8122) 
Variability Step time sd (ms) 15.14 (5.95) 17.46 (5.37) 
 
1.1045 (5.6919) 3.3846 (4.1152) 
 Stance time sd (ms) 17.13 (6.75) 22.39 (8.36) 
 
3.0466 (9.5435) 3.1035 (7.2859) 
 Step velocity sd (m/s) .04 (.01) .05 (.02) 
 
.0093 (.0198) .003 (.0152) 
 Step length sd (m) .017 (.005) .022 (.005)* 
 
.002 (.0054) .004 (.0073) 
Rhythm Step time (ms) 555 (41) 564 (50) 
 
-7.94 (23.57) -.71 (26.83) 
 Swing time (ms) 395 (28) 383 (25) 
 
-4.05 (15.7) -1.82 (19.81) 
 Stance time (ms) 717 (58) 746 (86) 
 
-12.11 (38.06) .42 (39.75) 
Asymmetry Step time asymmetry (ms) 16.34 (13.81) 19.32 (15.26) 
 
-2.0862 (1.5731) 2.8345 (13.9493) 
 Swing time asymmetry (ms) 11.73 (12.06) 14.7 (12.91) 
 
-.8917 (8.2367) -4.0865 (12.885) 
 Stance time asymmetry (ms) 12.51 (14.34) 14.51 (13.55) 
 
-1.2991 (8.4264) -4.6657 (15.225) 
Postural 
Control 
Step length asymmetry (m) .019 (.017) .032 (.029) 
 
.0001 (.0174) -.0055 (.029) 
Step width (m) .087 (.02) .108 (.033) 
 
.0036 (.0115) .0044 (.0102) 
Step width sd (m) .022 (.006) .017 (.006) 
 
-.0009 (.006) .003 (.0041) 
Dual-task   
   Pace Step velocity (m/s) 1.18 (.15) 1.03 (.25) 
 
.0069 (.1191) -.0572 (.1166) 
 Step Length (m) .67 (.06) .58 (.1)* 
 
-.0073 (.037) -.0386 (.0377) 
 Swing time sd (ms) 16.07 (5.77) 18 (6.32) 
 
-0.3433  (4.9679) 3.2742 (5.3954)) 
Variability Step time sd (ms) 19.69 (6.97) 19.03 (5.88) 
 
-.5607 (5.3776) 4.5919 (3.4984) 
 Stance time sd (ms) 24.72 (1.08) 25.16 (7.86) 
 
-.669 (8.7371) 6.268 (8.0965)* 
 Step velocity sd (m/s) .06 (.02) .05 (.02) 
 
-.003 (.0196) .0078 (.0168) 
 Step length sd (m) .023 (.007) .024 (.008) 
 
-.001 (.0081) .0042 (.008) 
Rhythm Step time (ms) 570 (41) 578 (62) 
 
-7.69 (27.65) -10.12 (35.11) 
 Swing time (ms) 399 (28) 385 (26) 
 
-3.21 (16.37) -10.03 (18.8) 
 Stance time (ms) 743 (60) 772 (104) 
 
-12.53 (4.82) -9.52 (54.26) 
Asymmetry Step time asymmetry (ms) 15.11 (14.16) 23.24 (13.27) 
 
-1.5097 (7.7394) -7.3832 (14.5856) 
 Swing time asymmetry (ms) 13.06 (13.6) 16.49 (11.37) 
 
-2.1902 (11.0507) -7.9209 (12.2665) 
 Stance time asymmetry (ms) 14.39 (14.04) 15.90 (11.38) 
 
-2.7824 (11.7396) -7.0867 (1.4869) 
Postural 
Control 
Step length asymmetry (m) .020 (.015) .033 (.030) 
 
.0010 (.0174) -.0059 (.0247) 
Step width (m) .093 (.02) .111 (.034) 
 
.0010 (.0164) .0054 (.0112) 
 Step width sd (m) .023 (.004) .018 (.007)*  -.0032 (.0043) .0004 (.0038)* 
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*signifies difference between PD and control groups p < .05. MoCA, Montreal Cognitive Assessment; 
GDS, Geriatric Depression Scale; MDS-UPDRS, Unified Parkinson’s Disease Rating Scale; Results 
expressed as mean (SD). 
 
Figure 1 Scatterplots between baseline sleep characteristics and change in single-task (Panels A and 
C) and dual-task (Panels B and D) step width variability over 36 months (36 month assessment – 
baseline assessment). Lines of best fit are indicated by solid black lines for PD participants and the 
dashed lines for controls. 
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Supplementary Table 1   Pearson correlations between baseline sleep and change in gait-related 
postural control variables, r (p) 
Condition Gait characteristic Sleep efficiency   Sleep fragmentation 
Control PD   Control PD 
Single Step width variability -.162 (.615) -.723 (.008)*   .227 (.479) .561 (.058) 
 
Step width -.630 (.028)* -.088 (.787) 
 
.454 (.138) .588 (.045)* 
 
Step length asymmetry .031 (.925) -.117 (.717) 
 
-.267 (.401) -.052 (.872) 
Dual Step width variability -.051 (.876) -.759 (.007)* 
 
-.032 (.922) .844 (.001)* 
 
Step width -.609 (.036)* -.417 (.203) 
 
.449 (.143) .543 (.084) 
  Step length asymmetry .250 (.434) -.230 (.497)   -.536 (.073) .050 (.884) 
       Supplementary Table 2   Partial correlations between baseline sleep and change in gait-related 
postural control variables controlling for global cognition (MoCA), r (p) 
Condition Gait characteristic Sleep efficiency   Sleep fragmentation 
Control PD   Control PD 
Single Step width variability -.188 (.580) -.750 (.013)*   .266 (.429) .625 (.053) 
 
Step width -.692 (.018)* -.118 (.746) 
 
.530 (.093) .570 (.086) 
 
Step length asymmetry .078 (.821) -.262 (.464) 
 
-.344 (.300) -.104 (.776) 
Dual Step width variability -.133 (.696) -.771 (.009)* 
 
.067 (.845) .886 (.001)* 
 
Step width -.688 (.019)* -.425 (.220) 
 
.544 (.083) .576 (.081) 
  Step length asymmetry .319 (.338) -.272 (.447)   -.649 (.031)* .134 (.713) 
 
 
 
